Indapamide
Indapamide is a thiazide-like diuretic taken by mouth. The US label read is for indapamide tablets and lists two uses: the treatment of hypertension, alone or in combination with other antihypertensive drugs, and the treatment of salt and fluid retention associated with congestive heart failure. No brand-name indapamide label was found in openFDA, so this page rests on a generic manufacturer's label. The label's separate passage on diuretics in pregnancy was not recorded.
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 5764; UNII F089I0511L. MeSH descriptor D007190 is Indapamide. Class: Thiazide-like Diuretic (FDA established pharmacologic class, RxClass). The label read is the indapamide tablets, Rising Pharma Holdings, Inc. label, effective 2023-06-26 in openFDA (application ANDA074461). Other indapamide labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 3 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 3
- Phase 3 or 4
- 2
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Completed | Unknown status | All statuses |
|---|---|---|---|
| Phase 2 | 1 | 0 | 1 |
| Phase 4 | 1 | 1 | 2 |
| All phases | 2 | 1 | 3 |
Conditions these trials study
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- Not reported
Claims and evidence
Context People for whom the US label of indapamide tablets lists an indication: hypertension, salt and fluid retention associated with congestive heart failure
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Patients with hypertension
- Patients with salt and fluid retention associated with congestive heart failure
- Excluded
- None stated
The US label of indapamide tablets, in the Rising Pharma Holdings, Inc. version dated 2023-06-26 in openFDA, lists the medicine for the treatment of hypertension, alone or in combination with other antihypertensive drugs, and for the treatment of salt and fluid retention associated with congestive heart failure.
Applies to Recipient not specified People for whom the US label of indapamide tablets lists an indication: hypertension, salt and fluid retention associated with congestive heart failure
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0]
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2023-06-26
- Source state
- Current
- Version fingerprint
f5d1e4a29dcccd9463f8c6ba4ab5a58c972367d951fddb28fa5c9bf7b86e3c43- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20230626.
- Retrieved
- Source effective date
- 2023-06-26
- Source state
- Current
- Version fingerprint
f5d1e4a29dcccd9463f8c6ba4ab5a58c972367d951fddb28fa5c9bf7b86e3c43- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
LOZOL
No label from the application holder was found in the openFDA label dataset for application NDA018538. This page does not show another labeler's label in its place.
WIDAPLIK
No label from the application holder was found in the openFDA label dataset for application NDA219423. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists hypertension as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified People for whom the US label of indapamide tablets lists an indication: hypertension, salt and fluid retention associated with congestive heart failure
The US label of indapamide tablets, in the Rising Pharma Holdings, Inc. version dated 2023-06-26 in openFDA, lists the medicine for the treatment of hypertension, alone or in combination with other antihypertensive drugs, and for the treatment of salt and fluid retention associated with congestive heart failure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists the treatment of salt and fluid retention associated with congestive heart failure as an indication: Heart failure
Applies to Recipient not specified People for whom the US label of indapamide tablets lists an indication: hypertension, salt and fluid retention associated with congestive heart failure
The US label of indapamide tablets, in the Rising Pharma Holdings, Inc. version dated 2023-06-26 in openFDA, lists the medicine for the treatment of hypertension, alone or in combination with other antihypertensive drugs, and for the treatment of salt and fluid retention associated with congestive heart failure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 2
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 3
Record details
- Record id
cardio:indapamide- Content hash
fd18e64fc98c979899df809427ca829d29c921ea8394766c35f548e227a22ec1